Clinical trials: Neuroendocrine Cancer, open to volunteers
Gastroenteropancreatic Neuroendocrine Tumor
Nutritional Status Assessment in Adult Patients Followed for Gastroenteropancreatic Neuroendocrine Tumors at Strasbourg University Hospital
Neuroendocrine tumors represent a heterogeneous group of tumors, of which gastrointestinal (gastroenteropancreatic) NETs are the most frequent.
- Trial name
- DENUTNE (NCT07302100)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Neurofibromatosis 1, Neurofibromatosis 2
The NF Registry Sponsored by the Children's Tumor Foundation
The NF Registry is a database of patient-reported symptoms, treatments, and experiences with their neurofibromatosis disease. It is a contact registry to relay clinical trial opportunities to targeted patient subgroups, and to…
- Conditions
- Neurofibromatosis 1, Neurofibromatosis 2, Schwannomatosis, NF2-related Schwannomatosis
- Trial name
- NCT01885767
- Where
- United States
- Volunteers
- 20,000 people
- Sponsor
- The Children's Tumor Foundation
Uveal Melanoma
Tebentafusp in HLA-A*0201 Positive Previously Untreated Metastatic Uveal Melanoma
This is a phase II open-label, single-arm, multi-center study of tebentafusp in HLA- A*0201 positive previously untreated (1L) untreated metastatic uveal melanoma (mUM) with an integrated circulating tumor DNA (ctDNA) biomarker.
- Trial name
- NCT06070012
- Testing
- Tebentafusp
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Diwakar Davar
Metastatic Melanoma
Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases
To evaluate tumor response, survival and adverse effects after precision radiotherapy (SBRT) in melanoma patients with ongoing PD-1 inhibitor treatment that have tumor progression.
- Trial name
- PROMMEL (NCT04793737)
- Testing
- Precision Radiation (SBRT)
- Where
- Sweden
- Volunteers
- 27 people
- Sponsor
- Karolinska University Hospital
CASA Intervention, Usual Care
Beyond Psychological Distress: Implementation of a Dyadic Behavioral Intervention Targeting Neuroendocrine and mRNA Translational Pathways in Late-Stage Breast Cancer
Specific Aim 1: Determine the effect of CASA on psychological distress (primary outcome) and on neuroendocrine, inflammatory, and translational control measures (secondary and exploratory outcomes) in LSBC-PR patients and…
- Trial name
- Beyond ID (NCT07828288)
- Testing
- The Caregivers-Patients Support to Cope with Advanced Cancer (CASA) is a five-session, manualized, meaning-centered psychotherapy developed for Puerto Rican patients and caregivers coping with advance, Control Condition. Includes CBT as the primary treatment approach for cancer patients and it is considered the usual care approach in these clinics, as well as one of the primar
- Volunteers
- 114 people, healthy volunteers welcome
- Sponsor
- Ponce Medical School Foundation, Inc.
Melanoma (Skin Cancer), NSCLC (Non-small Cell Lung Cancer)
Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade
This study is being done to test whether bright light therapy can be used to synchronize patients' circadian rhythms and allow ICB (immune-checkpoint blockade) therapy to be administered at a time in the circadian rhythm that…
- Trial name
- IIT BLT (NCT07661966)
- Testing
- Bright Light Therapy
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Weill Medical College of Cornell University
Cutaneous Melanoma
The MELAcare Study: A New Method for Surveillance of Melanoma Patients
The aim of this study is to evaluate a new method of follow-up for patients with low and intermediate risk (stages IA-IIA) melanoma.
- Trial name
- NCT05253872
- Testing
- The MelaCare intervention
- Where
- Denmark
- Volunteers
- 378 people
- Sponsor
- Herlev and Gentofte Hospital
Metastatic Melanoma
IL-17 Blockade to Decrease irAEs (REPLAY)
The primary objective of this study is to determine the safety and feasibility of administering an IL-17A (human IgG1κ) monoclonal antibody, (Secukinumab, Cosentyx®) to participants with metastatic melanoma who have previously…
- Trial name
- REPLAY (NCT07237594)
- Testing
- Secukinumab Injection
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Duke University
Melanoma
A Study to Learn About the Long-Term Health of Adult Participants From a Previous Study of a New Melanoma Treatment
This study is researching the long-term effects of a combination of experimental drugs called fianlimab and cemiplimab. The study is being conducted in patients with advanced skin cancer (melanoma) who had previously been treated…
- Trial name
- NCT06848088
- Testing
- Fianlimab+cemiplimab
- Where
- 11 sites in United States, Ireland
- Volunteers
- 48 people
- Sponsor
- Regeneron Pharmaceuticals
Vestibular Schwannoma, Ototoxicity
Radiosurgery Induced Ototoxicity in Patients Treated for a Vestibular Schwannoma
The investigators aim to study the impact of stereotactic radiosurgery, for the treatment of vestibular Schwannoma, on the cochlear, vestibular, gustatory, and facial nerve functions and compare it with a conservatively treated…
- Trial name
- NCT05641441
- Testing
- Stereotactic radiosurgery
- Where
- Switzerland
- Volunteers
- 258 people
- Sponsor
- University Hospital, Geneva
PDL1 Gene Mutation, Non Small Cell Lung Cancer
177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors
This is a Phase 0/1, First-in-Human (FIH), study to evaluate safety, tolerability of 177Lu-RAD204 in participants with selected solid tumors, and to determine the MTD and/or recommended dose for future exploration.
- Conditions
- PDL1 Gene Mutation, Non Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), TNBC, Triple Negative Breast Cancer
- Trial name
- NCT06305962
- Testing
- 177Lu-RAD204
- Where
- 6 sites in Australia
- Volunteers
- 30 people
- Sponsor
- Radiopharm Theranostics, Ltd
NENS
NALIRIFOX as Second-Line Chemotherapy in Extrapulmonary High-grade Neuroendocrine Neoplasms: a Prospective, Single-center, Single-arm Trial
High-grade neuroendocrine neoplasms (NENs) comprise both well-differentiated grade 3 neuroendocrine tumors (G3 NETs) and poorly differentiated neuroendocrine carcinomas (NECs).
- Trial name
- NCT07077551
- Testing
- NALIRIFOX
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Gastrointestinal Neuroendocrine Carcinoma, Adjuvant Treatment
Oxaliplatin-Based Adjuvant Therapy for Gastrointestinal Neuroendocrine Carcinoma**
Patients with pathologically-confirmed gastrointestinal neuroendocrine carcinoma will be enrolled, to explore the efficacy and safety of oxaliplatin-based doublet chemotherapy in the adjuvant treatment of gastrointestinal…
- Conditions
- Gastrointestinal Neuroendocrine Carcinoma, Adjuvant Treatment, Resection
- Trial name
- NCT07891572
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Peking Union Medical College Hospital
Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma
IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
To find the highest tolerable dose of IACS-6274 that can be given alone, in combination with bevacizumab and paclitaxel, or in combination with capivasertib to patients who have solid tumors.
- Conditions
- Advanced Endometrial Carcinoma, Advanced Head and Neck Squamous Cell Carcinoma, Advanced Malignant Solid Neoplasm, Advanced Melanoma
- Trial name
- NCT05039801
- Testing
- Bevacizumab, Glutaminase-1 Inhibitor IACS-6274, Paclitaxel
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- M.D. Anderson Cancer Center
Unresectable/Metastatic Melanoma
Duration of Anti-PD-1 Therapy in Metastatic Melanoma
The purpose of this study is to compare the effects on patients with metastatic melanoma of taking a government approved and paid-for PD-1 inhibitor intermittently, with taking the same type of agent continuously.
- Trial name
- STOP-GAP (NCT02821013)
- Testing
- Intermittent PD-1 inhibitor therapy, Continuous PD-1 inhibitor therapy
- Where
- 30 sites in Australia, Canada
- Volunteers
- 614 people
- Sponsor
- Canadian Cancer Trials Group
Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative
Intratumoral N17350 in Advanced Solid Tumors
The goal of this clinical trial is to learn if N17350 works to treat advanced solid tumors in adults. It will also learn about the safety of N17350 and help determine the best dose to use in future studies.
- Conditions
- Neoplasms, Solid Tumor, Breast Neoplasms, Triple-Negative, Squamous Cell Carcinoma of Skin, Melanoma
- Trial name
- OP-NEU-101 (NCT07339176)
- Testing
- N17350
- Where
- 9 sites in United States, Australia
- Volunteers
- 275 people
- Sponsor
- Onchilles Pharma Inc
Neuroendocrine Carcinoma
Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary
there is a need for improving chemotherapy regimen for metastatic G3 NEC of GEP and Unknown origin and this goal may be achieved through more "personalized" chemotherapy regimen.the hypothesis is that mFOLFIRINOX regimen could be…
- Trial name
- FOLFIRINEC (NCT04325425)
- Testing
- FOLFOXIRI Protocol, Cisplatin injection
- Where
- 6 sites in France
- Volunteers
- 218 people
- Sponsor
- Centre Hospitalier Universitaire Dijon
Vestibular Schwannoma
Evolution of Balance and Vestibular Function in Patients Treated With Gammaknife Radiosurgery for Vestibular Schwannoma
Vestibular schwannomas are benign lesions of the ponto-cerebellar angle that are potentially dangerous because of their growth in a cramped space and the compressive phenomena they can cause.
- Trial name
- EQUI-GAMMA (NCT04859335)
- Testing
- gammaknife radiosurgery
- Where
- France
- Volunteers
- 50 people
- Sponsor
- University Hospital, Toulouse
Melanoma of Skin
Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age.
The primary objective of the study is to analyse a local cohort of patients aged 18-39 years with melanoma diagnosis in order to determine the prevalence of the disease in this age group.
- Trial name
- MELA_2025 (NCT06994208)
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Ente Ospedaliero Ospedali Galliera
Grade I Meningioma, Grade II Meningioma
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors.
- Conditions
- Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm
- Trial name
- HiPPI (NCT04278118)
- Testing
- Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Emory University